Showing results (121-130 of 150) with videos related to
Sort By:
Pageof 15
Nature Communications|June 17, 2026
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trialSarah M H Einerhand, Hamza Ali, Stephen Q Wong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CancerRoland Seiler, Ewan A Gibb, Natalie Q Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO StudyChantal F Stockem, Alberto Gil-Jimenez, Hamza Ali, et al.The Lancet. Oncology|September 24, 2020
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialThomas Powles, Michiel S van der Heijden, Daniel Castellano, et al.JMIR Research Protocols|July 24, 2025
Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled TrialLilian Bot, Josine G van Mill, Laetitia J C A Smarius, et al.Nature Medicine|February 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trialJan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts, et al.European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.Nature Medicine|October 13, 2020
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trialNick van Dijk, Alberto Gil-Jimenez, Karina Silina, et al.Nature Medicine|February 2, 2023
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trialJeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann, et al.Pageof 15